Google and its sister companies are making substantial investments towards artificial intelligence in healthcare; the Trump administration seeks to remove protections for transgender individuals that allow equal access to healthcare; researchers identified 104 high-risk schizophrenia genes.
Google and its sister companies have made a substantial investment, predicted by analysts to be billions of dollars, towards artificial intelligence in the healthcare field, NPR reported. Verily, which was already supplied a billion dollars in funding earlier this year, stands out as a key player; it is currently working on software that can diagnose diabetic retinopathy, tools to monitor blood sugar in diabetic patients, and surgical robots that learn from each operation. Google has an advantage over other companies as it has already collected and compiled data from billions of users.HHS is expected to propose a rule that would facilitate the option for physicians, hospitals, and insurance companies to deny care or coverage to transgender patients as well as women who have had abortions, according to The Hill. The new health regulations could be published as early as next week. The rule is expected to weaken or remove an anti-discrimination provision established in the Affordable Care Act that protected individuals from being denied coverage related to transgender status. Advocates are concerned that the proposal could reverse the progress made in ensuring that transgender patients receive equal access to care.Researchers at Vanderbilt University Department of Molecular Physiology and Biophysics and the Vanderbilt Genetics Institute have identified 104 high-risk genes for schizophrenia, ScienceDaily reported. The discovery supports the idea that schizophrenia is a developmental disease that can potentially be diagnosed and treated before symptoms arise. Future research could be directed towards repurposing current drugs in an effort to improve treatment of the disorder or toward identification of cell types in the brain that are active along the development pathway.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen